The Wolverine stack (BPC-157 + TB-500): what the evidence actually shows

What people mean by the Wolverine stack

The name is internet shorthand, not a clinical term. It describes running BPC-157 and TB-500 (a fragment of thymosin beta-4) together, usually for injury recovery, on the theory that the two act on different parts of tissue repair.

• BPC-157 is a synthetic pentadecapeptide derived from a sequence found in gastric juice. Its healing effects are reported in rodent tendon, muscle and gut injury models.
• TB-500 is a synthetic fragment of thymosin beta-4, a protein involved in actin regulation and cell migration. Its repair effects likewise come from animal work.
• Neither is an approved medicine in the United States, the EU, the UK, Canada or Australia. Neither has a published randomized controlled trial in humans for injury repair.
• Both are on the World Anti-Doping Agency prohibited list — BPC-157 was added explicitly, and TB-500 falls under S2 growth factors. Tested athletes face sanctions.
• The FDA moved bulk BPC-157 into the category of substances raising significant safety risks for compounding, which is why compounding pharmacies stopped supplying it.

What the evidence actually shows

This is the part most write-ups skip. The animal literature is genuinely interesting; the human literature effectively does not exist.

• BPC-157's tendon and ligament results come from rat models with transected tendons — impressive in that setting, and not transferable to a human dose or timeline.
• Thymosin beta-4 reached human trials for pressure ulcers, dry eye and cardiac indications. Those studied the full protein, not the TB-500 fragment sold online, and did not establish efficacy for sports injury.
• There is no published human pharmacokinetic study for either compound, so half-life, bioavailability and an appropriate interval are unknown rather than merely debated.
• There is no trial of the combination. Any claim that the two are synergistic in people is extrapolation from separate animal models.
• Purity is a second problem stacked on top: material sold as research chemical has no regulated identity or content standard. Independent testing is the only way to know what is in a vial.

Risks worth naming plainly

Absence of published harm is not evidence of safety when there is no human trial to report harm in the first place.

• Unknown long-term effects: growth-promoting and angiogenic mechanisms are exactly the mechanisms oncologists watch. No long-term human safety data exists for either compound.
• Unregulated supply: counterfeit and under-dosed vials are common, and an unsterile compounded vial carries infection risk on top of that.
• Anti-doping sanctions for anyone in a tested sport.
• Injection-site reactions, and the general risks of self-injection with non-pharmaceutical material.
• Masked injury: anything that reduces pain without repairing the structure invites a return to load too early.

If you are already running it, record it properly

We do not recommend a dose or a schedule, and this page will not give you one. What a tracker can do is make the record accurate enough to be useful to a clinician later.

• Record the vial's concentration in mg/mL at reconstitution, and log every dose in both mg and the volume actually drawn.
• Log injection sites and rotate them; record the lot number so a change in response can be traced to a change in material.
• Note the injury itself — pain scores, range of motion, load tolerated — since that is the only outcome that matters and the only thing you can measure.
• Keep the storage record: reconstitution date, refrigeration, any warm shipping. Degraded material explains a lot of disappointing results.
• Tell your clinician. Unlicensed peptides are the thing patients most often omit and clinicians most want to know.

References

• BPC-157: a review of the preclinical literature (Seiwerth S, et al.)
• Thymosin beta-4: mechanisms and clinical trial experience (Goldstein AL, et al.)
• FDA — Bulk drug substances nominated for compounding: BPC-157 category 2
• World Anti-Doping Agency — Prohibited List